Provides More Comprehensive, Accurate Answers
PROMETHEUS Celiac PLUS combines serologic and genetic testing in one convenient test
- Comprehensive serum antibody profile combines 5 serological markers (IgG, IgA, tTG, EMA and total serum IgA)
- Only Prometheus genetic testing quantifies the relative risk of disease for every patient
- A negative predictive value (NPV) of 95% to 100% allows for ruling out celiac disease for life1
Now You Can Asses Your Patients’ Risk
| Category Number | DQ Genotype Category | Increased Risk Over General Population2,3 | Relative Risk |
|---|---|---|---|
| 8 | DQ2 homozygous | 31x | Extremely High |
| 7 | DQ2/other high-risk gene | 16x | Very High |
| 6 | DQ2/DQ8 | 10x | Very High |
| 5 | DQ8 homozygous | 10x | High |
| 4 | DQ2 heterozygous | 10x | High |
| 3 | DQ8 heterozygous | 2x | Moderate |
| 2 | DQ2/other low-risk gene | <1x | Low |
| 1 | DQ2-, DQ8- | <0.1x | Extremely Low |
Most celiac patients carry either the DQ2 haplotype (about 95% of celiacs) or the DQ8 haplotype (about 5% of celiacs). There are two DQ2 haplotypes, but only one DQ8 haplotype—specific combinations may confer different risks for the development of celiac disease, as shown above.
Research advises ordering full HLA-DQA1 and DQB1 typing and should also have other clinical correlates including positive serology (gluten challenged) with or without abnormal duodenal biopsy.
References:
1. Kaukinen K, Partanen J, Mäki M, Collin P. HLA-DQ typing in the diagnosis of celiac disease. Am J Gastroenterol. 2002;97(3):695-699.
2. Pietzak M, Schofield T. HLA-DQ2 homozygotes are associated with a 31-fold increased risk of EMA positivity in a large sample of sera (n = 4152) from patients at risk for celiac disease [DDW abstract]. Gastroenterology. 2007;132(7):2585.
3. Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med. 2003;163(3):286-292.
Sample insurance correspondence for PROMETHEUS® Celiac Plus
- These tests have not been cleared or approved by the US FDA. The tests are used for clinical purposes and should not be regarded as investigational or for research. Prometheus Biosciences is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high-complexity clinical laboratory testing and is accredited by the College of American Pathologists (CAP).
- This material is provided for general information purposes only as an educational service for healthcare physicians and their patients. It is not intended as a substitute for medical advice and/or consultation with a physician.